Doctor discusses Ivermectin success in India, questions Canada’s COVID approach
No matter where you stand on how to best handle pandemic policy, Dr. Da Costa’s experience and view is worth a listen.
No matter where you stand on how to best handle pandemic policy, Dr. Da Costa’s experience and view is worth a listen.
In Dr. Ozaki’s recent speech, he declared that ivermectin has demonstrated significant benefits in reducing infections and deaths where the regimen is prophylactically administered for another indication. The head of the Metropolitan Medical Association declared that while clinical trials were important, it was time to greenlight doctors to prescribe ivermectin in association with giving the patient informed consent.
Just as Galileo proved with his telescope that the earth was NOT the center of the Universe in 1616; today, the data from India shows that Ivermectin is effective, much more so than the vaccines. It not only prevents death, but it also prevents COVID infections, and it also is effective against the Delta Variant.
Two doses (300 μg/kg/dose in a gap of 72 hours) of ivermectin chemoprophylaxis reduced COVID-19 infection by 83% among HCWs for one month. Ivermectin is a safe and effective strategy to prevent COVID-19, in the containment of pandemic alongside vaccine. Further research is required to guide the frequency of chemoprevention, acceptability, and cost-effectiveness in the community setting.
The death rate from COVID-19 is dramatically low at United Memorial Medical Center in Houston, TX compared to other hospitals across the nation and the world. Despite Dr. Joseph Varon’s popularity on TV, news personalities avoid questions of why he’s having success treating his patients. As it turns out, he’s using drugs the WHO and CDC recommend against.
During the first wave, the primary antiviral used was HCQ, and during the second wave (after Facebook censored his account where he was communicating with others in a large nation) they shifted to ivermectin due to HCQ controversies. Similarly to the way Dr. Brian Tyson attacked COVID-19 with an early multi-drug regimen, numerous other medicines, including aspirin, were used. Of Dr. Shah’s 8,000 or so patients, only 5 succumbed to COVID-19. This is notably similar to the results of Dr. Didier Raoult.
Ivermectin is on the WHO’s list of essential medicines and has a high safety profile with more than 3.7 billion doses having been distributed in more than 30 years.
This is pulled straight from the same playbook as the propaganda against HCQ. Even if you’re not sure that one or both of these medicines is effective despite uniformly positive results when applied as early treatment, you should at least recognize the pattern, scratch your head, and question whether there is…maybe…just possibly some perverse incentive like power or profit from vaccines driving this absurdity.
Source: India Today Author: Prabhash K Dutta Hydroxychloroquine, the malaria drug touted as a magical Covid-19 cure by former US President Donald Trump last year,
Just as fast as new cases materialized so has the decline thanks in part to a coordinated public health strategy that includes proactive testing, home visits, and medication kits that include ivermectin.
“The significant decline is a tremendous achievement in the fight against COVID-19 and further bolsters our appeal to undertake mass distribution of ivermectin to our people.”
With ivermectin now on the national Indian COVID-19 list of recommended treatments for COVID-19, a few states have gone to the next level and included the low-cost, generic drug approved throughout the world as a parasite fighter as a prophylactic targeting SARS-CoV-2, the virus behind COVID-19.
TrialSite hosted the first international Ivermectin for Covid Summit webinar on Sunday, May 23rd 2021. The event was widely attended with medical experts presenting from around the world to a global audience of interested parties in the thousands.
TrialSite hosted the first international Ivermectin for Covid Summit webinar on Sunday, May 23rd 2021. The event was widely attended with medical experts presenting from around the world to a global audience of interested parties in the thousands.
Both Goa and Karnataka are rolling out mass Ivermectin programs in a bid to reduce infection, transmission, and death rates associated with COVID-19. TrialSite reported two days ago that the State of Goa embraced the national Ivermectin guidelines, and as reported in The Mint and other outlets, Vishwajit Rane, Goa’s Health Minister, declared that all people 18 years and up would have access to the generic drug regardless of COVID-19 status in an aggressive bid to lower infection rates and total deaths associated with SARS-CoV-2.
So, what’s different between Maharashtra and Delhi with respect to the rest of India and South Asia? Instead of relying on HCQ and IVM, many doctors and health officials in Maharashtra and Delhi pushed the expensive and profitable remdesivir drug. Due to its cost and recommended time of usage, remdesivir is not used either as a prophylaxis or for early outpatient treatment. And unlike the cheap and easy-to-produce HCQ and IVM, remdesivir is difficult to replace when it runs out.
HCQ is effective for COVID-19. The probability that an ineffective treatment generated results as positive as the 235 studies to date is estimated to be 1 in 6 quadrillion (p = 0.00000000000000018).
Early treatment is most successful, with 100% of 29 studies reporting a positive effect (13 statistically significant in isolation) and an estimated reduction of 65% in the effect measured (death, hospitalization, etc.) using a random effects meta-analysis, RR 0.35 [0.25-0.50].
92% of Randomized Controlled Trials (RCTs) for early, PrEP, or PEP treatment report positive effects, the probability of this happening for an ineffective treatment is 0.0017.
It would be a historically amazing feat of maneuvering bureaucracy, worthy of its own epic book, movie, or perhaps a campfire song, to have wrangled that much data out of those hospitals with highly variable regulations and procedures, nearly all of which are in the U.S. healthcare system.
While HCQ looks very safe overall for COVID-19 patients, it looks safest when used as a prophylactic or therapeutic for early stage COVID-19 patients, once again affirming the Primary HCQ Hypothesis as the strongest version of the HCQ Hypothesis.
“I am deeply troubled that the WHO made this hasty decision on guidance before reviewing all available data,” said Pierre Kory, MD, MPH, president and chief medical officer of the FLCCC.
“Their recommendation ignores the evidence, creates more controversy, and will only lead to continuing suffering and death from COVID-19. There are now over 24 randomized trials results
that have been reported to the Unitaid/WHO team yet todays guidance was inexcusably based on a faulty analysis of just 16 of the available trials. Further, these erroneous findings directly conflict
with numerous other peer-reviewed expert analyses that have found the data overwhelmingly demonstrates that ivermectin saves lives from COVID-19. There is no reason not to recommend it
for everyone as a safe drug for prevention and treatment.”
As part of Mission Sagar – IV, Indian Naval Ship Jalashwa arrived at Port Ehoala, Madagascar on 22 March 2021. The ship will deliver a consignment of 1,000 Metric Tonne of rice and 100,000 Hydroxychloroquine tablets in response to an appeal made by Madagascar for assistance to deal with natural calamities.
Santin’s endorsement is not only important but broad. He said he has seen ivermectin work at every stage of COVID — preventing it, eliminating early infection, quelling the destructive cytokine storm in late infection, and helping about a dozen patients so far who suffered months after COVID.
The group that didn’t take the ivermectin, over 3 months it was fifty-eight percent. Fifty-eight percent of those doctors, nurses and orderlies contracted coronavirus.
In the 788 group, the same doctors, nurses and orderlies across the 4 hospitals, the number of infections that they had, was zero. ZERO, that were treated with ivermectin.
Reductions in covid-19 deaths and infections may be possible by using ivermectin. Employing ivermectin early on may reduce the number of people progressing to severe disease. The apparent safety and low cost suggest that ivermectin could have an impact on the SARS-CoV-2 pandemic globally.
The science shows that ivermectin works. Over 40 randomized trials and observational studies from around the world attest to its efficacy against the novel coronavirus. Meta-analyses by four separate research groups, including ours, found an average reduction in mortality of between 68%-75%. And 10 of 13 randomized controlled trials found statistically significant reductions in time to viral clearance, an effect not associated with any other COVID-19 therapeutic. Furthermore, ivermectin has an unparalleled safety record and low cost, which should negate any fears or resistance to immediate adoption.
India has conquered the disease with hydroxychloroquine and ivermectin, uses a traditional vaccine, exports experimental vaccines for these idiotic Westerners … There are 1,230 deaths per million inhabitants over 65 (six times less than in France). If we had listened to Raoult and followed the Indian model, today we would have 500 cases of covid per day and 75,000 fewer deaths …
Early treatment intervention with hydoxychloroquine & Ivermectin appears to have played a major role in control in India, precipitating local herd immunity.
Ivermectin is an effective treatment for COVID-19. The probability that an ineffective treatment generated results as positive as the 42 studies to date is estimated to be 1 in 4 trillion (p = 0.00000000000023).
We conclude that two-dose ivermectin prophylaxis at a dose of 300 μg/kg body weight with a gap of 72 hours was associated with a 73% reduction of SARS-CoV-2 infection among HCWs in the following one month. Chemoprophylaxis has relevance in the containment of pandemic. This is an intervention worth replicating at other centers until a vaccine is widely available.
With such a rate of contamination, we are faced with a scenario of collective quasi-immunity managed with a broad prescription of early and prophylactic treatment based on hydroxychloroquine. With a contamination rate of 56%, mortality is 549 people per million inhabitants. Last December, the Institut Pasteur estimated the rate of the French population to be contaminated at 11.3% [1]. Mortality in France is 1200 [2] people per million inhabitants. The population of Delhi is five times more contaminated with mortality more than two times lower compared to France. The case fatality rate with early treatment in Delhi, which is 0.1%, is close to the rate estimated by Professor Raoult in the case of early treatment.
Source: Reviews in Cardiovascular Medicine Peter A. McCullough, Paul E. Alexander, Robin Armstrong, Cristian Arvinte, Alan F. Bain, Richard P. Bartlett, Robert L. Berkowitz, Andrew
Source: ivmmeta.com Figure 1. A. Random effects meta-analysis excluding late treatment. Simplified dosages are shown for comparison, these are the total dose in the first two days
Source: TrialSiteNews Author: Mary Beth Pfeiffer She is a gynecologist. He is a surgeon. They are married and both 77 years old. In mid-November, they
Hydroxychloroquine, an anti-malarial drug, when combined with chloroquine has the potential to be the major game-changer in medical history.
Source: HCQMeta.com HCQ is effective for COVID-19 when used early: meta-analysis of 156 studies (Version 28, December 4, 2020) • HCQ is effective for COVID-19.
We should learn from the countries that have been using the drug. The dramatic fall in death rates that occurred after hydroxychloroquine treatment was initiated in countries like India, Brazil and Ecuador can no longer be ignored. To do so, and to continue to interfere with a doctor’s right to prescribe HCQ to their patients, is reckless and immoral.
Source: Journal of Marine Medical Society Date of Submission 23-Aug-2020 Date of Decision 18-Sep-2020 Date of Acceptance 29-Sep-2020 Date of Web Publication 06-Nov-2020 Correspondence Address:Vivek
Source: Science Direct Dr. Deba PrasadDhibarMD(Assistant Professor)aDr. NavneetAroraMD(Senior Resident)aDr. ArpitKakkarDNB(Senior Resident)aDr. NeerajSinglaMD(Assistant Professor)bDr. RitinMohindraMD(Assistant Professor)bDr. VikasSuriMD(Additional Professor)bDr. AshishBhallaMD(Professor)bDr. NavneetSharmaMD(Professor)bDr. Mini PSinghMD(Professor)cDr. AjayPrakashPhd(Assistant Professor)dDr. LakshmiPVMMD(Professor)eDr. BikashMedhiMD(Professor)d
Source: HCQmeta.com • HCQ is effective for COVID-19. The probability that an ineffective treatment generated results as positive as the 132 studies to date is
“The government has re-purposed the drug HCQ for treatment of mild (but high-risk cases) and for moderate cases.”